Havih Envirosciences Partners with Andhra Pradesh Government to Establish BSL-4 Anti-Infective Drug Development Facility
Key Insights
Havih Envirosciences (search), a Maxwell Biosciences (search) subsidiary, has formed a strategic partnership with the Government of Andhra Pradesh (search) to establish advanced pharmaceutical research and production capabilities in the state.
The collaboration provides Havih access to advanced R&D laboratories and underground Biosafety Level 4 (BSL-4) biocontainment facilities at APCARL (search)'s Pulivendula campus in YSR Kadapa district.
The partnership focuses on developing and supplying next-generation anti-infective medicines (search) for early use within Andhra Pradesh, with manufacturing and export operations centered in India.
Havih Envirosciences (search), a subsidiary of Maxwell Biosciences (search), has announced a strategic partnership with the Government of Andhra Pradesh (search) to establish advanced pharmaceutical research and production capabilities in the state. The collaboration was formalized through an agreement with the Andhra Pradesh Centre for Advanced Research on Livestock Limited (APCARL (search)) on November 21, 2025.
Advanced Biocontainment Research Infrastructure
Under the agreement, APCARL (search) will provide Havih access to advanced R&D laboratories and underground Biosafety Level 4 (BSL-4) biocontainment facilities at its Pulivendula campus in YSR Kadapa district. These BSL-4 facilities represent the highest level of biological containment, enabling research on the most dangerous pathogens under maximum security conditions.
The partnership positions Havih to develop and supply next-generation anti-infective medicines (search) for early use within Andhra Pradesh, with manufacturing and export operations centered in India. This approach aligns with India's strategic goals of building indigenous pharmaceutical capabilities while serving global markets.
Strategic Vision for India's Pharmaceutical Leadership
"India's growth trajectory and Prime Minister Modi's Viksit Bharat @ 2047 vision make this exactly the right moment to pair world-class innovation platforms with sovereign, India-based execution," said Scotch McClure, Founder, CEO & Chairman of Maxwell Biosciences (search). "Through Havih and APCARL (search), we are anchoring advanced biocontainment research, first-in-class drug development and globally relevant intellectual property in India—while building a high-skill workforce capable of sustaining long-term wage growth and export leadership."
McClure emphasized that the partnership reflects how global technology platforms and India-first innovation can work together to strengthen both public health and economic resilience. The collaboration is designed to translate frontier immune-inspired science into durable, real-world solutions using Andhra Pradesh's scientific infrastructure and policy alignment.
Building Indigenous Innovation Capabilities
Havih Envirosciences (search) operates as an Indian citizen-owned and operated life sciences company focused on India-first innovation in advanced anti-infective medicines (search), biosafety solutions and environmental resilience technologies. The company's mission centers on strengthening India's leadership in branded pharmaceutical research and development by enabling high-margin innovation and advanced containment research.
The partnership emphasizes biosafety, biodefense and public-health preparedness while supporting international export markets from an India-based innovation core. Through strategic collaborations with government research institutions and global technology partners, Havih is building a next-generation R&D and production ecosystem designed to deliver durable economic value and globally relevant intellectual property.
Technology Platform and Future Applications
Maxwell Biosciences (search), Havih's parent company, has developed a proprietary technology platform featuring immune-inspired small molecules called Claromers (search)®. These molecules are designed to mimic and enhance the body's natural defenses, destroying pathogenic bacteria (search), viruses (search), fungi (search) and biofilms (search) without harming healthy cells or the microbiome.
The Claromers (search)® technology offers several advantages including no refrigeration requirements, safety for the commensal microbiome, and high stability in harsh environments. Originally developed for critical infectious diseases (search), the technology is now entering commercial deployment across multiple sectors including cosmetics, personal care, medical coatings and biodefense.
Maxwell Biosciences (search) has active collaborative agreements with the US military and governments worldwide, with FDA clinical trials planned for 2026. The company's AI-first platform enables rapid innovation against resistant pathogens, offering scalable, shelf-stable and microbiome-resilient solutions.